#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Michigan’s 24% wholesale tax is driving down cannabis sales volumes and tax revenue, which may reduce state funding for cannabis testing, quality assurance, and regulatory oversight that directly affect product safety for patients. Lower market activity could also incentivize consumers to return to illicit markets with unregulated products, exposing patients to contaminated cannabis without lab verification for potency or pesticides. Clinicians should be aware that tax policy significantly influences medication access and product quality for patients using cannabis therapeutically, making cannabis taxation a relevant public health consideration in clinical care discussions.
Michigan’s 24% wholesale tax on cannabis continues to constrain the legal market, with preliminary data showing statewide revenue declined 14.8% month-over-month to $206.18 million in March 2025. This sustained tax burden reduces incentives for legal market participation and may drive patients and consumers toward illicit sources where product quality, safety, and potency testing cannot be assured. For clinicians, a shrinking legal market has implications for patient access to regulated products with verified cannabinoid profiles and contaminant screening, potentially compromising the ability to provide consistent dosing recommendations. The revenue decline also affects state funding for cannabis regulatory infrastructure and public health initiatives that support safe product standards. Clinicians should counsel patients about the importance of purchasing from licensed dispensaries despite potentially higher prices, as legal products offer documented safety and quality assurance compared to unregulated alternatives.
“When a state’s tax burden exceeds what the illicit market charges, we see patients return to unregulated sources where we have no quality control, no cannabinoid testing, and no ability to counsel on drug interactions, and that’s a clinical failure regardless of the revenue projections.”
💊 Michigan’s recent 24% wholesale tax has created a significant market contraction that warrants clinical attention, as the 14.8% monthly revenue decline may reflect both reduced supply and price escalation in the legal market. While higher taxes ostensibly support public health infrastructure and regulation, the practical effect of pricing out consumers may paradoxically shift demand toward untaxed illicit sources, limiting the state’s ability to monitor product quality, potency, and contamination risks—concerns directly relevant to patient safety. Clinicians should recognize that cannabis tax policy operates as an indirect but meaningful determinant of their patients’ access to tested, regulated products versus potentially unsafe alternatives, though data on actual market migration to illicit channels in Michigan remains limited. When counseling patients about cannabis use, providers may need to explicitly discuss the local regulatory and pricing landscape as a factor influencing product safety and consistency. Understanding these economic pressures on the legal supply chain can inform more nuance
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: